Laurent Fischer compensation by year
Adverum Biotechnologies Summary Compensation Table · all 3 fiscal years held| Component | FY2022 | FY2023 | FY2024 |
|---|---|---|---|
| Salary | $645,800 | $671,600 | $691,795 |
| Bonus | $0 | $0 | $0 |
| Stock awards | $0 | $0 | $171,363 |
| Option awards | $1,929,411 | $530,193 | $2,839,252 |
| Non-equity incentive | $329,358 | $342,531 | $415,080 |
| Pension and deferred compensation | $0 | $0 | $0 |
| All other | $2,070 | $2,153 | $13,800 |
| Total | $2,906,639 | $1,546,477 | $4,131,290 |
Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: Adverum Biotechnologies, Inc. DEF 14A filed April 28, 2025, accession 0001140361-25-016005, and prior-year filings. Open the filing on EDGAR.
How this page was built: the Adverum Biotechnologies, Inc. filed document, accession 0001140361-25-016005. Every figure is read from that document and cited to the page and table it appears in. Filed April 28, 2025.
Equity holdings
unvested awards at FY2024 year-end| Type | Unvested units | Value at year-end | Exercise price |
|---|---|---|---|
| PSU | 45,333 | $211,705 | — |
| Option | 200,000 | — | $7.15 |
| Option | 110,420 | — | $19.90 |
| Option | 52,313 | — | $7.50 |
| Option | 16,876 | — | $10.90 |
| Option | 10,500 | — | $12.90 |
| Option | 18,375 | — | $12.90 |
| Option | 2,840 | — | $134.40 |
Per the Outstanding Equity Awards at Fiscal Year-End table in Adverum Biotechnologies, Inc.'s FY2024 proxy; value at the fiscal year-end close, as the company printed it.
Insider transactions since the last proxy
35 Form 4 lines since the FY2024 proxy (filed April 28, 2025)current to 2026-11-21 · updated nightly
| Date | Transaction | Plan | Shares | Price | Held after |
|---|---|---|---|---|---|
| 2025-12-09 | Grant or award | — | 500,000 | $0.00 | 522,666 |
| 2025-12-09 | Exercise or conversion | — | 150,000 | $4.20 | 351,513 |
| 2025-12-09 | U | — | 351,513 | — | 0 |
| 2025-12-09 | U | — | 25,000 | — | 0 |
| 2025-12-09 | U | — | 522,666 | — | 0 |
| 2025-12-09 | Disposition to the issuer derivative | — | 93,000 | — | 0 |
| 2025-12-09 | Disposition to the issuer derivative | — | 200,000 | — | 0 |
| 2025-12-09 | Exercise or conversion derivative | — | 150,000 | — | 0 |
The 8 most recent of 35 lines, each as reported on the Form 4. "10b5-1" marks a trade the filing reports under a pre-arranged trading plan. View every Form 4 filing on EDGAR →
Adverum Biotechnologies’s named executive officers, FY2024
as the company reported each| Named executive officer | Role | FY2024 total |
|---|---|---|
| Laurent Fischer · this page | President and Chief Executive Officer | $4,131,290 |
| Kishor Soparkar | Chief Operating Officer | $1,843,178 |
| Linda Rubinstein | Chief Financial Officer | $1,605,925 |
| Setareh Seyedkazemi | Chief Development Officer | $1,598,442 |
| Rabia Ozden | Chief Medical Officer | $1,305,133 |
Board service
Adverum Biotechnologies board · FY2024How this board is paid
Company policy: Adverum Biotechnologies pays directors a $40,000 cash retainer. As stated in Adverum Biotechnologies's FY2024 proxy.
The full Adverum Biotechnologies compensation record
free company briefThis page is one person within Adverum Biotechnologies's record. The company brief lists every named executive, each linking to their own page.
Peer companies
named in the Adverum Biotechnologies proxy · each links to its own free briefCompensation, the day it’s disclosed
The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.
How this record is built
Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are Adverum Biotechnologies's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.